Tags : JHLbiotech

Biosimilars Pharma

JHL Biotech’s Trastuzumab Biosimilar (JHL1188) Receives CHMP Positive Scientific Advice

Shots: JHL1188 gets CHMP approval for its global Phase III clinical trial in metastatic breast cancer  JHL1188 is a proposed biosimilar to trastuzumab, which is marketed by Roche under the trade name Herceptin  JHL is developing 7 biosimilar including JHL1188, which is for metastatic breast cancer Click here to read full press release/ article | Ref: Prnewswire […]Read More